Stocks · News reference
Co-Diagnostics Announces Publication Of Peer-Reviewed Study Using SARAGENE Human Papillomavirus High Risk Test Manufactured By CoSara Diagnostics
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Co-Diagnostics, Inc. (CODX)
Filed: 2026-11-10 AccNo: 0001493152-26-050868 Size: 311 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has rescheduled its third quarter 2026 financial results release and conference call to November 10, 2026.
Co-Diagnostics Expands South Asian Market Presence via CoSara
Co-Diagnostics, Inc. is expanding its reach in India and South Asia through its joint venture, CoSara Diagnostics, with plans for a direct sales team and upcoming regulatory milestones.
Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date
Co-Diagnostics, Inc. will release its third quarter 2026 financial results on November 12, 2026.